Published in Mol Med on February 25, 2011
Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med (2011) 1.41
Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol (2012) 1.05
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol (2011) 1.05
Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells. J Biol Chem (2012) 0.96
The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult Scler Int (2014) 0.93
Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei. Bioorg Med Chem Lett (2012) 0.88
Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int J Nanomedicine (2012) 0.86
Epigenetics and the modulation of neuroinflammation. Neurotherapeutics (2013) 0.83
Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod (2013) 0.80
Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest. J Cell Physiol (2015) 0.80
Expression profiles of the nuclear receptors and their transcriptional coregulators during differentiation of neural stem cells. Horm Metab Res (2012) 0.79
Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability? Acta Neuropathol Commun (2014) 0.78
Intracellular Protein Shuttling: A Mechanism Relevant for Myelin Repair in Multiple Sclerosis? Int J Mol Sci (2015) 0.77
Epigenetic Drugs for Multiple Sclerosis. Curr Neuropharmacol (2016) 0.75
Neurobehavioral burden of multiple sclerosis with nanotheranostics. Neuropsychiatr Dis Treat (2015) 0.75
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. Biomed Res Int (2016) 0.75
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol (2006) 14.33
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 10.26
Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med (2007) 6.61
Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol (2002) 4.95
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov (2008) 4.43
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med (2005) 4.43
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood (2008) 3.95
CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol (2007) 3.77
Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol (2002) 3.63
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A (2002) 2.91
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther (2007) 2.90
Distribution of histone deacetylases 1-11 in the rat brain. J Mol Neurosci (2007) 2.44
Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat Rev Drug Discov (2008) 2.30
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A (2003) 2.21
HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci U S A (2009) 2.14
IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol (2004) 2.11
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med (2006) 2.11
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A (2008) 2.10
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00
Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J Neurosci (2005) 2.00
Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest (1998) 1.99
Signals to promote myelin formation and repair. Nat Rev Neurol (2010) 1.95
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.89
HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ (2006) 1.82
Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today (2005) 1.80
Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood (2006) 1.77
Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann N Y Acad Sci (2007) 1.67
Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J (2000) 1.66
Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord (2005) 1.62
The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer (2003) 1.48
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42
Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience (2007) 1.42
HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res (2008) 1.36
Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol (2010) 1.30
Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29
Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs (2008) 1.25
Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med (2010) 1.21
Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J Immunol (2003) 1.20
Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis (2009) 1.16
The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ (2009) 1.12
Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood (2000) 1.12
The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology (2010) 1.10
Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res (2007) 1.10
Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics (2006) 1.10
Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem (2003) 1.08
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci (2010) 1.07
Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest (1997) 1.03
Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol (2008) 0.96
Dendritic cells have the option to express IDO-mediated suppression or not. Blood (2005) 0.96
Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells. Inflamm Res (2005) 0.90
Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role. J Neurol Sci (2009) 0.87
The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system. Neurobiol Dis (1999) 0.87
Molecular pathogenesis of multiple sclerosis. J Neuroimmunol (1999) 0.85
Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. Int J Immunopathol Pharmacol (2009) 0.84
Characterization of the pro-inflammatory signaling induced by protein acetylation in microglia. Neurochem Int (2006) 0.79
Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. Ann Oncol (2001) 0.78
Emerging oral agents for multiple sclerosis. Am J Manag Care (2010) 0.77
Anti-myelin antibodies in multiple sclerosis: clinically useful? J Neurol Neurosurg Psychiatry (2006) 0.75
Leptin is induced in the ischemic cerebral cortex and exerts neuroprotection through NF-kappaB/c-Rel-dependent transcription. Stroke (2008) 1.72
Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol (2006) 1.67
The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci (2005) 1.34
Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction. J Biol Chem (2005) 1.33
Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem (2010) 1.27
Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis (2009) 1.16
STAT1 is activated in neurons after ischemia and contributes to ischemic brain injury. J Cereb Blood Flow Metab (2002) 1.08
Neurological basis of AMP-dependent thermoregulation and its relevance to central and peripheral hyperthermia. J Cereb Blood Flow Metab (2012) 1.08
Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Mol Pharmacol (2011) 1.07
Studies on the neuroprotective action of kynurenine mono-oxygenase inhibitors in post-ischemic brain damage. Adv Exp Med Biol (2003) 1.04
Ischemic neuroprotection by TRPV1 receptor-induced hypothermia. J Cereb Blood Flow Metab (2012) 1.03
Poly(ADP-ribose) catabolism triggers AMP-dependent mitochondrial energy failure. J Biol Chem (2009) 1.03
Functional study in a yeast model of a novel succinate dehydrogenase subunit B gene germline missense mutation (C191Y) diagnosed in a patient affected by a glomus tumor. Hum Mol Genet (2009) 1.01
Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice. J Cereb Blood Flow Metab (2006) 1.01
Poly(ADP-ribose) polymerase-1 is a nuclear epigenetic regulator of mitochondrial DNA repair and transcription. Mol Pharmacol (2011) 1.00
G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacology (2010) 0.96
Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol (2006) 0.95
Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol (2009) 0.95
Insight into molecular and functional properties of NMNAT3 reveals new hints of NAD homeostasis within human mitochondria. PLoS One (2013) 0.94
Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J (2009) 0.93
A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. J Immunol (2007) 0.92
Neuroprotective effects of propofol in models of cerebral ischemia: inhibition of mitochondrial swelling as a possible mechanism. Anesthesiology (2006) 0.92
Neither energy collapse nor transcription underlie in vitro neurotoxicity of poly(ADP-ribose) polymerase hyper-activation. Neurochem Int (2006) 0.90
Induction of CD83+CD14+ nondendritic antigen-presenting cells by exposure of monocytes to IFN-alpha. J Immunol (2008) 0.89
Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol (2002) 0.89
Inhibition of poly(ADP-ribose) glycohydrolase by gallotannin selectively up-regulates expression of proinflammatory genes. Mol Pharmacol (2004) 0.89
PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. Mult Scler (2011) 0.88
AMP-dependent hypothermia affords protection from ischemic brain injury. J Cereb Blood Flow Metab (2012) 0.86
High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer (2008) 0.86
Antidromic vasodilatation and the migraine mechanism. J Headache Pain (2011) 0.85
18β-glycyrrhetic acid inhibits immune activation triggered by HMGB1, a pro-inflammatory protein found in the tear fluid during conjunctivitis and blepharitis. Ocul Immunol Inflamm (2011) 0.85
On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives. ChemMedChem (2008) 0.84
Poly(ADP-ribosyl)ation regulates heat shock factor-1 activity and the heat shock response in murine fibroblasts. Biochem Cell Biol (2006) 0.84
Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage. Toxicol Lett (2003) 0.83
Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis? Trends Mol Med (2011) 0.83
1B/(-)IRE DMT1 expression during brain ischemia contributes to cell death mediated by NF-κB/RelA acetylation at Lys310. PLoS One (2012) 0.82
Activation of the histaminergic H3 receptor induces phosphorylation of the Akt/GSK-3 beta pathway in cultured cortical neurons and protects against neurotoxic insults. J Neurochem (2009) 0.82
Brain ischemic preconditioning does not require PARP-1. Stroke (2009) 0.81
Indoleamine 2,3-dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes. J Invest Dermatol (2009) 0.81
GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses. PLoS One (2013) 0.81
Human Langerhans cells are immature in melanoma sentinel lymph nodes. Blood (2012) 0.80
Relevance of high-mobility group protein box 1 to neurodegeneration. Int Rev Neurobiol (2007) 0.80
Anticonvulsant effect of AMP by direct activation of adenosine A1 receptor. Exp Neurol (2013) 0.79
Dipotassium Glycyrrhizate Inhibits HMGB1-Dependent Inflammation and Ameliorates Colitis in Mice. PLoS One (2013) 0.79
Glucose deprivation converts poly(ADP-ribose) polymerase-1 hyperactivation into a transient energy-producing process. J Biol Chem (2013) 0.77
Mild activation of poly(ADP-ribose) polymerase (PARP) is neuroprotective in rat hippocampal slice models of ischemic tolerance. Eur J Neurosci (2012) 0.77
Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation. Horm Cancer (2014) 0.77
PARP inhibition delays progression of mitochondrial encephalopathy in mice. Neurotherapeutics (2014) 0.76
Carboxymethyl beta-glucan binds to corneal epithelial cells and increases cell adhesion to laminin and resistance to oxidative stress. Cornea (2007) 0.75